1
|
Hobson AD, McPherson MJ, Waegell W, Goess CA, Stoffel RH, Li X, Zhou J, Wang Z, Yu Y, Hernandez A, Bryant SH, Mathieu SL, Bischoff AK, Fitzgibbons J, Pawlikowska M, Puthenveetil S, Santora LC, Wang L, Wang L, Marvin CC, Hayes ME, Shrestha A, Sarris KA, Li B. Correction to "Design and Development of Glucocorticoid Receptor Modulators as Immunology Antibody-Drug Conjugate Payloads". J Med Chem 2023; 66:6011. [PMID: 37058612 DOI: 10.1021/acs.jmedchem.3c00598] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/16/2023]
|
2
|
Hobson AD, McPherson MJ, Waegell W, Goess CA, Stoffel RH, Li X, Zhou J, Wang Z, Yu Y, Hernandez A, Bryant SH, Mathieu SL, Bischoff AK, Fitzgibbons J, Pawlikowska M, Puthenveetil S, Santora LC, Wang L, Wang L, Marvin CC, Hayes ME, Shrestha A, Sarris KA, Li B. Design and Development of Glucocorticoid Receptor Modulators as Immunology Antibody-Drug Conjugate Payloads. J Med Chem 2022; 65:4500-4533. [PMID: 35133822 DOI: 10.1021/acs.jmedchem.1c02099] [Citation(s) in RCA: 15] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Glucocorticoid receptor modulators (GRM) are the first-line treatment for many immune diseases, but unwanted side effects restrict chronic dosing. However, targeted delivery of a GRM payload via an immunology antibody-drug conjugate (iADC) may deliver significant efficacy at doses that do not lead to unwanted side effects. We initiated our α-TNF-GRM ADC project focusing on identifying the optimal payload and a linker that afforded stable attachment to both the payload and antibody, resulting in the identification of the synthetically accessible maleimide-Gly-Ala-Ala linker. DAR 4 purified ADCs were shown to be more efficacious in a mouse contact hypersensitivity model than the parent α-TNF antibody. Analysis of P1NP and corticosterone biomarkers showed there was a sufficient therapeutic window between efficacy and unwanted effects. In a chronic mouse arthritis model, α-TNF-GRM ADCs were more efficacious than both the parent α-TNF mAb and an isotype control bearing the same GRM payload.
Collapse
Affiliation(s)
- Adrian D Hobson
- AbbVie Bioresearch Center, 381 Plantation Street, Worcester, Massachusetts 01605, United States
| | - Michael J McPherson
- AbbVie Bioresearch Center, 381 Plantation Street, Worcester, Massachusetts 01605, United States
| | - Wendy Waegell
- AbbVie Bioresearch Center, 381 Plantation Street, Worcester, Massachusetts 01605, United States
| | - Christian A Goess
- AbbVie Bioresearch Center, 381 Plantation Street, Worcester, Massachusetts 01605, United States
| | - Robert H Stoffel
- AbbVie Bioresearch Center, 381 Plantation Street, Worcester, Massachusetts 01605, United States
| | - Xiang Li
- WuXi AppTec, 168 Nanhai Road, Tianjin Economic-Technological Development Area TEDA, Tianjin 300457, China
| | - Jian Zhou
- WuXi AppTec, 168 Nanhai Road, Tianjin Economic-Technological Development Area TEDA, Tianjin 300457, China
| | - Zhongyuan Wang
- WuXi AppTec, 168 Nanhai Road, Tianjin Economic-Technological Development Area TEDA, Tianjin 300457, China
| | - Yajie Yu
- WuXi AppTec, 168 Nanhai Road, Tianjin Economic-Technological Development Area TEDA, Tianjin 300457, China
| | - Axel Hernandez
- AbbVie Bioresearch Center, 381 Plantation Street, Worcester, Massachusetts 01605, United States
| | - Shaughn H Bryant
- AbbVie Bioresearch Center, 381 Plantation Street, Worcester, Massachusetts 01605, United States
| | - Suzanne L Mathieu
- AbbVie Bioresearch Center, 381 Plantation Street, Worcester, Massachusetts 01605, United States
| | - Agnieszka K Bischoff
- AbbVie Bioresearch Center, 381 Plantation Street, Worcester, Massachusetts 01605, United States
| | - Julia Fitzgibbons
- AbbVie Bioresearch Center, 381 Plantation Street, Worcester, Massachusetts 01605, United States
| | - Martyna Pawlikowska
- AbbVie Bioresearch Center, 381 Plantation Street, Worcester, Massachusetts 01605, United States
| | - Sujiet Puthenveetil
- AbbVie Bioresearch Center, 381 Plantation Street, Worcester, Massachusetts 01605, United States
| | - Ling C Santora
- AbbVie Bioresearch Center, 381 Plantation Street, Worcester, Massachusetts 01605, United States
| | - Lu Wang
- AbbVie Bioresearch Center, 381 Plantation Street, Worcester, Massachusetts 01605, United States
| | - Lu Wang
- AbbVie Bioresearch Center, 381 Plantation Street, Worcester, Massachusetts 01605, United States
| | - Christopher C Marvin
- AbbVie, Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States
| | - Martin E Hayes
- AbbVie Bioresearch Center, 381 Plantation Street, Worcester, Massachusetts 01605, United States
| | - Anurupa Shrestha
- AbbVie, Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States
| | - Kathy A Sarris
- AbbVie, Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States
| | - Biqin Li
- AbbVie Bioresearch Center, 381 Plantation Street, Worcester, Massachusetts 01605, United States
| |
Collapse
|
3
|
Gupta P, Jiang ZK, Yang B, Manzuk L, Rosfjord E, Yao J, Lemon L, Noorbehesht K, David J, Puthenveetil S, Casavant JM, Muszynska E, Li F, Leal M, Sapra P, Giddabasappa A. Targeting and pharmacology of an anti-IL13Rα2 antibody and antibody-drug conjugate in a melanoma xenograft model. MAbs 2021; 13:1958662. [PMID: 34347577 PMCID: PMC8344738 DOI: 10.1080/19420862.2021.1958662] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
IL13Rα2 is a cell surface tumor antigen that is overexpressed in multiple tumor types. Here, we studied biodistribution and targeting potential of an anti-IL13Rα2 antibody (Ab) and anti-tumor activity of anti-IL13Rα2-antibody-drug conjugate (ADC). The anti-IL13Rα2 Ab was labeled with fluorophore AF680 or radioisotope 89Zr for in vivo tracking using fluorescence molecular tomography (FMT) or positron emission tomography (PET) imaging, respectively. Both imaging modalities showed that the tumor was the major uptake site for anti-IL13Rα2-Ab, with peak uptake of 5–8% ID and 10% ID/g as quantified from FMT and PET, respectively. Pharmacological in vivo competition with excess of unlabeled anti-IL13Rα2-Ab significantly reduced the tumor uptake, indicative of antigen-specific tumor accumulation. Further, FMT imaging demonstrated similar biodistribution and pharmacokinetic profiles of an auristatin-conjugated anti-IL13Rα2-ADC as compared to the parental Ab. Finally, the anti-IL13Rα2-ADC exhibited a dose-dependent anti-tumor effect on A375 xenografts, with 90% complete responders at a dose of 3 mg/kg. Taken together, both FMT and PET showed a favorable biodistribution profile for anti-IL13Rα2-Ab/ADC, along with antigen-specific tumor targeting and excellent therapeutic efficacy in the A375 xenograft model. This work shows the great potential of this anti-IL13Rα2-ADC as a targeted anti-cancer agent.
Collapse
Affiliation(s)
- Parul Gupta
- Global Science & Technology - Comparative Medicine, Pfizer Inc., San Diego, CA, USA.,Biomedicine Design, Pfizer Inc., San Diego, CA, USA
| | - Ziyue Karen Jiang
- Global Science & Technology - Comparative Medicine, Pfizer Inc., San Diego, CA, USA
| | - Bing Yang
- Global Science & Technology - Comparative Medicine, Pfizer Inc., San Diego, CA, USA
| | - Lisa Manzuk
- Global Science & Technology - Comparative Medicine, Pfizer Inc., San Diego, CA, USA
| | - Edward Rosfjord
- Oncology Research and Development, Pfizer Inc., Pearl River, NY, USA
| | - Johnny Yao
- Oncology Research and Development, Pfizer Inc., Pearl River, NY, USA
| | - Luanna Lemon
- Oncology Research and Development, Pfizer Inc., Pearl River, NY, USA
| | - Kavon Noorbehesht
- Global Science & Technology - Comparative Medicine, Pfizer Inc., San Diego, CA, USA
| | - John David
- Global Science & Technology - Comparative Medicine, Pfizer Inc., San Diego, CA, USA
| | | | | | - Elwira Muszynska
- Oncology Research and Development, Pfizer Inc., Pearl River, NY, USA
| | - Fengping Li
- Biomedicine Design, Pfizer Inc., San Diego, CA, USA
| | | | - Puja Sapra
- Oncology Research and Development, Pfizer Inc., Pearl River, NY, USA
| | - Anand Giddabasappa
- Global Science & Technology - Comparative Medicine, Pfizer Inc., San Diego, CA, USA
| |
Collapse
|
4
|
Graziani EI, Sung M, Ma D, Narayanan B, Marquette K, Puthenveetil S, Tumey LN, Bikker J, Casavant J, Bennett EM, Charati MB, Golas J, Hosselet C, Rohde CM, Hu G, Guffroy M, Falahatpisheh H, Finkelstein M, Clark T, Barletta F, Tchistiakova L, Lucas J, Rosfjord E, Loganzo F, O'Donnell CJ, Gerber HP, Sapra P. PF-06804103, A Site-specific Anti-HER2 Antibody-Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers. Mol Cancer Ther 2020; 19:2068-2078. [PMID: 32747418 DOI: 10.1158/1535-7163.mct-20-0237] [Citation(s) in RCA: 28] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2020] [Revised: 06/04/2020] [Accepted: 07/14/2020] [Indexed: 11/16/2022]
Abstract
The approval of ado-trastuzumab emtansine (T-DM1) in HER2+ metastatic breast cancer validated HER2 as a target for HER2-specific antibody-drug conjugates (ADC). Despite its demonstrated clinical efficacy, certain inherent properties within T-DM1 hamper this compound from achieving the full potential of targeting HER2-expressing solid tumors with ADCs. Here, we detail the discovery of PF-06804103, an anti-HER2 ADC designed to have a widened therapeutic window compared with T-DM1. We utilized an empirical conjugation site screening campaign to identify the engineered ĸkK183C and K290C residues as those that maximized in vivo ADC stability, efficacy, and safety for a four drug-antibody ratio (DAR) ADC with this linker-payload combination. PF-06804103 incorporates the following novel design elements: (i) a new auristatin payload with optimized pharmacodynamic properties, (ii) a cleavable linker for optimized payload release and enhanced antitumor efficacy, and (iii) an engineered cysteine site-specific conjugation approach that overcomes the traditional safety liabilities of conventional conjugates and generates a homogenous drug product with a DAR of 4. PF-06804103 shows (i) an enhanced efficacy against low HER2-expressing breast, gastric, and lung tumor models, (ii) overcomes in vitro- and in vivo-acquired T-DM1 resistance, and (iii) an improved safety profile by enhancing ADC stability, pharmacokinetic parameters, and reducing off-target toxicities. Herein, we showcase our platform approach in optimizing ADC design, resulting in the generation of the anti-HER2 ADC, PF-06804103. The design elements of identifying novel sites of conjugation employed in this study serve as a platform for developing optimized ADCs against other tumor-specific targets.
Collapse
Affiliation(s)
| | - Matthew Sung
- Pfizer Inc., Oncology Research & Development, Pearl River, New York.
| | - Dangshe Ma
- Pfizer Inc., Oncology Research & Development, Pearl River, New York
| | - Bitha Narayanan
- Pfizer Inc., Oncology Research & Development, Pearl River, New York
| | | | | | - L Nathan Tumey
- Pfizer Inc., World Wide Medicinal Chemistry, Groton, Connecticut
| | - Jack Bikker
- Pfizer Inc., World Wide Medicinal Chemistry, Groton, Connecticut
| | - Jeffrey Casavant
- Pfizer Inc., World Wide Medicinal Chemistry, Groton, Connecticut
| | - Eric M Bennett
- Pfizer Inc., BioMedicine Design, Cambridge, Massachusetts
| | - Manoj B Charati
- Pfizer Inc., Oncology Research & Development, Pearl River, New York
| | - Jonathon Golas
- Pfizer Inc., Oncology Research & Development, Pearl River, New York
| | | | - Cynthia M Rohde
- Pfizer Inc., Drug Safety Research & Development, Pearl River, New York
| | - George Hu
- Pfizer Inc., Drug Safety Research & Development, Pearl River, New York
| | - Magali Guffroy
- Pfizer Inc., Drug Safety Research & Development, Pearl River, New York
| | | | | | - Tracey Clark
- Pfizer Inc., BioMedicine Design, Groton, Connecticut
| | | | | | - Judy Lucas
- Pfizer Inc., Oncology Research & Development, Pearl River, New York
| | - Edward Rosfjord
- Pfizer Inc., Oncology Research & Development, Pearl River, New York
| | - Frank Loganzo
- Pfizer Inc., Oncology Research & Development, Pearl River, New York
| | | | | | - Puja Sapra
- Pfizer Inc., Oncology Research & Development, Pearl River, New York.
| |
Collapse
|
5
|
Puthenveetil S. Utilizing Solid-Phase to Enable High-Throughput, Site-Specific Conjugation and Dual-Labeled Antibody and Fab Conjugates. Methods Mol Biol 2020; 2078:99-112. [PMID: 31643052 DOI: 10.1007/978-1-4939-9929-3_7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
For therapeutic and diagnostic applications, site-specific antibody conjugates have proven superior for both the ease of characterization as well as for optimal biophysical and therapeutic properties. Screening multiple antibodies on multiple sites with multiple linker-drugs can become very tedious and time-consuming. As solid-phase reactions are best suited to simplify multistep reactions, readily available protein A/L agarose beads can be utilized to generate site-specific, antibody -drug conjugates on engineered cysteines. Multiple site-specific labels on an antibody with either fluorophore or other-linker drugs is highly desired to evaluate antibody trafficking or payload-synergy for therapeutics. Utilizing solid-phase conjugation, a simple method to generate dual-labeled, site-specific antibody and Fab conjugates from antibody with engineered cysteine is also been described.
Collapse
Affiliation(s)
- Sujiet Puthenveetil
- AbbVie Bioresearch Center, R&D, Worcester, MA, USA.
- Pfizer, Inc., Groton, CT, USA.
| |
Collapse
|
6
|
Abstract
Incomplete removal of free (unconjugated) drug or drug-linker species used to prepare ADCs results in contaminated ADC samples which may pose a risk for toxicity. Due to the extreme potency of typical small molecule toxins employed in ADCs, even relatively low levels of free drug contaminants in ADC samples have been hypothesized to result in nonspecific (i.e., off-target) activity in biological systems. It is possible for trace levels of certain free drug species to persist in final ADC samples despite the inclusion of common purification steps during the preparation processes. Therefore, methods for the detection, quantification, and removal of residual free drug present in ADC samples are ultimately required for the preparation of safe and efficacious final ADC drug products. Herein we report general methods for the detection and removal of such contaminants.
Collapse
Affiliation(s)
| | | | - Sujiet Puthenveetil
- AbbVie Bioresearch Center, R&D, Worchester, MA, USA
- Pfizer, Inc., Groton, CT, USA
| | - L Nathan Tumey
- Department of Pharmacy and Pharmaceutical Sciences, Binghamton University, Binghamton, NY, USA
- Pfizer, Inc., Groton, CT, USA
| |
Collapse
|
7
|
Tumey LN, Li F, Rago B, Han X, Loganzo F, Musto S, Graziani EI, Puthenveetil S, Casavant J, Marquette K, Clark T, Bikker J, Bennett EM, Barletta F, Piche-Nicholas N, Tam A, O'Donnell CJ, Gerber HP, Tchistiakova L. Site Selection: a Case Study in the Identification of Optimal Cysteine Engineered Antibody Drug Conjugates. AAPS J 2017; 19:1123-1135. [PMID: 28439809 DOI: 10.1208/s12248-017-0083-7] [Citation(s) in RCA: 42] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/09/2017] [Accepted: 04/03/2017] [Indexed: 11/30/2022]
Abstract
As the antibody drug conjugate (ADC) community continues to shift towards site-specific conjugation technology, there is a growing need to understand how the site of conjugation impacts the biophysical and biological properties of an ADC. In order to address this need, we prepared a carefully selected series of engineered cysteine ADCs and proceeded to systematically evaluate their potency, stability, and PK exposure. The site of conjugation did not have a significant influence on the thermal stability and in vitro cytotoxicity of the ADCs. However, we demonstrate that the rate of cathepsin-mediated linker cleavage is heavily dependent upon site and is closely correlated with ADC hydrophobicity, thus confirming other recent reports of this phenomenon. Interestingly, conjugates with high rates of cathepsin-mediated linker cleavage did not exhibit decreased plasma stability. In fact, the major source of plasma instability was shown to be retro-Michael mediated deconjugation. This process is known to be impeded by succinimide hydrolysis, and thus, we undertook a series of mutational experiments demonstrating that basic residues located nearby the site of conjugation can be a significant driver of succinimide ring opening. Finally, we show that total antibody PK exposure in rat was loosely correlated with ADC hydrophobicity. It is our hope that these observations will help the ADC community to build "design rules" that will enable more efficient prosecution of next-generation ADC discovery programs.
Collapse
Affiliation(s)
- L Nathan Tumey
- Binghamton University, School of Pharmacy and Pharmaceutical Sciences, P.O. Box 6000, Binghamton, New York, 13902-6000, USA.
| | - Fengping Li
- Biomedicine Design, Pfizer, Inc., Cambridge, Massachusetts, 06379, USA
| | - Brian Rago
- Worldwide Research and Development, Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut, 06379, USA
| | - Xiaogang Han
- PKDM, Amgen, Inc., 360 Binney Street, AMA 1, Cambridge, Massachusetts, 02142, USA
| | - Frank Loganzo
- Oncology Research and Development, Pfizer, Inc., 401 N. Middletown Rd., Pearl River, New York, 10965, USA
| | - Sylvia Musto
- Oncology Research and Development, Pfizer, Inc., 401 N. Middletown Rd., Pearl River, New York, 10965, USA
| | - Edmund I Graziani
- Worldwide Research and Development, Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut, 06379, USA
| | | | - Jeffrey Casavant
- Worldwide Research and Development, Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut, 06379, USA
| | | | - Tracey Clark
- Worldwide Research and Development, Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut, 06379, USA
| | - Jack Bikker
- International Flavors and Fragrances, 521 West 57th Street, New York, New York, 10019, USA
| | - Eric M Bennett
- Biomedicine Design, Pfizer, Inc., Cambridge, Massachusetts, 06379, USA
| | - Frank Barletta
- Worldwide Research and Development, Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut, 06379, USA
| | | | - Amy Tam
- Biomedicine Design, Pfizer, Inc., Cambridge, Massachusetts, 06379, USA
| | - Christopher J O'Donnell
- Worldwide Research and Development, Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut, 06379, USA
| | - Hans Peter Gerber
- Maverick Therapeutics, Inc, 3260 Bayshore Blvd, Brisbane, California, 94005, USA
| | | |
Collapse
|
8
|
Tumey LN, Leverett CA, Vetelino B, Li F, Rago B, Han X, Loganzo F, Musto S, Bai G, Sukuru SCK, Graziani EI, Puthenveetil S, Casavant J, Ratnayake A, Marquette K, Hudson S, Doppalapudi VR, Stock J, Tchistiakova L, Bessire AJ, Clark T, Lucas J, Hosselet C, O’Donnell CJ, Subramanyam C. Optimization of Tubulysin Antibody-Drug Conjugates: A Case Study in Addressing ADC Metabolism. ACS Med Chem Lett 2016; 7:977-982. [PMID: 27882194 PMCID: PMC5108037 DOI: 10.1021/acsmedchemlett.6b00195] [Citation(s) in RCA: 50] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2016] [Accepted: 06/22/2016] [Indexed: 01/19/2023] Open
Abstract
As part of our efforts to develop new classes of tubulin inhibitor payloads for antibody-drug conjugate (ADC) programs, we developed a tubulysin ADC that demonstrated excellent in vitro activity but suffered from rapid metabolism of a critical acetate ester. A two-pronged strategy was employed to address this metabolism. First, the hydrolytically labile ester was replaced by a carbamate functional group resulting in a more stable ADC that retained potency in cellular assays. Second, site-specific conjugation was employed in order to design ADCs with reduced metabolic liabilities. Using the later approach, we were able to identify a conjugate at the 334C position of the heavy chain that resulted in an ADC with considerably reduced metabolism and improved efficacy. The examples discussed herein provide one of the clearest demonstrations to-date that site of conjugation can play a critical role in addressing metabolic and PK liabilities of an ADC. Moreover, a clear correlation was identified between the hydrophobicity of an ADC and its susceptibility to metabolic enzymes. Importantly, this study demonstrates that traditional medicinal chemistry strategies can be effectively applied to ADC programs.
Collapse
Affiliation(s)
- L. Nathan Tumey
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | - Carolyn A. Leverett
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | - Beth Vetelino
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | - Fengping Li
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | - Brian Rago
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | - Xiaogang Han
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | - Frank Loganzo
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | - Sylvia Musto
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | - Guoyun Bai
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | | | - Edmund I. Graziani
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | - Sujiet Puthenveetil
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | - Jeffrey Casavant
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | - Anokha Ratnayake
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | - Kimberly Marquette
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | - Sarah Hudson
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | | | - Joseph Stock
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | | | - Andrew J. Bessire
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | - Tracey Clark
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | - Judy Lucas
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | - Christine Hosselet
- Pfizer, Inc., 445 Eastern Point Road, Groton, Connecticut 06379, United States
| | | | | |
Collapse
|
9
|
Puthenveetil S, Loganzo F, He H, Dirico K, Green M, Teske J, Musto S, Clark T, Rago B, Koehn F, Veneziale R, Falahaptisheh H, Han X, Barletta F, Lucas J, Subramanyam C, O'Donnell CJ, Tumey LN, Sapra P, Gerber HP, Ma D, Graziani EI. Natural Product Splicing Inhibitors: A New Class of Antibody-Drug Conjugate (ADC) Payloads. Bioconjug Chem 2016; 27:1880-8. [PMID: 27412791 DOI: 10.1021/acs.bioconjchem.6b00291] [Citation(s) in RCA: 42] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
There is a considerable ongoing work to identify new cytotoxic payloads that are appropriate for antibody-based delivery, acting via mechanisms beyond DNA damage and microtubule disruption, highlighting their importance to the field of cancer therapeutics. New modes of action will allow a more diverse set of tumor types to be targeted and will allow for possible mechanisms to evade the drug resistance that will invariably develop to existing payloads. Spliceosome inhibitors are known to be potent antiproliferative agents capable of targeting both actively dividing and quiescent cells. A series of thailanstatin-antibody conjugates were prepared in order to evaluate their potential utility in the treatment of cancer. After exploring a variety of linkers, we found that the most potent antibody-drug conjugates (ADCs) were derived from direct conjugation of the carboxylic acid-containing payload to surface lysines of the antibody (a "linker-less" conjugate). Activity of these lysine conjugates was correlated to drug-loading, a feature not typically observed for other payload classes. The thailanstatin-conjugates were potent in high target expressing cells, including multidrug-resistant lines, and inactive in nontarget expressing cells. Moreover, these ADCs were shown to promote altered splicing products in N87 cells in vitro, consistent with their putative mechanism of action. In addition, the exposure of the ADCs was sufficient to result in excellent potency in a gastric cancer xenograft model at doses as low as 1.5 mg/kg that was superior to the clinically approved ADC T-DM1. The results presented herein therefore open the door to further exploring splicing inhibition as a potential new mode-of-action for novel ADCs.
Collapse
Affiliation(s)
| | - Frank Loganzo
- Oncology-Rinat Research & Development, Pfizer , 401 North Middletown Road, Pearl River, New York 10965, United States
| | | | | | | | | | - Sylvia Musto
- Oncology-Rinat Research & Development, Pfizer , 401 North Middletown Road, Pearl River, New York 10965, United States
| | | | | | | | - Robert Veneziale
- Drug Safety Research and Development, Pfizer , 401 North Middletown Road, Pearl River, New York 10977, United States
| | - Hadi Falahaptisheh
- Drug Safety Research and Development, Pfizer , 401 North Middletown Road, Pearl River, New York 10977, United States
| | | | | | - Judy Lucas
- Oncology-Rinat Research & Development, Pfizer , 401 North Middletown Road, Pearl River, New York 10965, United States
| | | | | | | | - Puja Sapra
- Oncology-Rinat Research & Development, Pfizer , 401 North Middletown Road, Pearl River, New York 10965, United States
| | - Hans Peter Gerber
- Oncology-Rinat Research & Development, Pfizer , 401 North Middletown Road, Pearl River, New York 10965, United States
| | - Dangshe Ma
- Oncology-Rinat Research & Development, Pfizer , 401 North Middletown Road, Pearl River, New York 10965, United States
| | | |
Collapse
|
10
|
Bessire AJ, Ballard TE, Charati M, Cohen J, Green M, Lam MH, Loganzo F, Nolting B, Pierce B, Puthenveetil S, Roberts L, Schildknegt K, Subramanyam C. Determination of Antibody–Drug Conjugate Released Payload Species Using Directed in Vitro Assays and Mass Spectrometric Interrogation. Bioconjug Chem 2016; 27:1645-54. [DOI: 10.1021/acs.bioconjchem.6b00192] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Andrew J. Bessire
- Pharmacokinetics, Dynamics and Metabolism, ∥Worldwide Medicinal Chemistry, and ¶Pharmaceutical Sciences Chemical R&D, Pfizer Worldwide R&D, Groton, Connecticut 06340, United States
- Oncology Research Unit, and ⊥Bioprocess R&D, Pfizer Worldwide R&D, Pearl River, New York 10965, United States
- Worldwide Medicinal Chemistry, and §Global Biotherapeutics Technologies, Pfizer Worldwide R&D, Cambridge, Massachusetts 02139, United States
| | - T. Eric Ballard
- Pharmacokinetics, Dynamics and Metabolism, ∥Worldwide Medicinal Chemistry, and ¶Pharmaceutical Sciences Chemical R&D, Pfizer Worldwide R&D, Groton, Connecticut 06340, United States
- Oncology Research Unit, and ⊥Bioprocess R&D, Pfizer Worldwide R&D, Pearl River, New York 10965, United States
- Worldwide Medicinal Chemistry, and §Global Biotherapeutics Technologies, Pfizer Worldwide R&D, Cambridge, Massachusetts 02139, United States
| | - Manoj Charati
- Pharmacokinetics, Dynamics and Metabolism, ∥Worldwide Medicinal Chemistry, and ¶Pharmaceutical Sciences Chemical R&D, Pfizer Worldwide R&D, Groton, Connecticut 06340, United States
- Oncology Research Unit, and ⊥Bioprocess R&D, Pfizer Worldwide R&D, Pearl River, New York 10965, United States
- Worldwide Medicinal Chemistry, and §Global Biotherapeutics Technologies, Pfizer Worldwide R&D, Cambridge, Massachusetts 02139, United States
| | - Justin Cohen
- Pharmacokinetics, Dynamics and Metabolism, ∥Worldwide Medicinal Chemistry, and ¶Pharmaceutical Sciences Chemical R&D, Pfizer Worldwide R&D, Groton, Connecticut 06340, United States
- Oncology Research Unit, and ⊥Bioprocess R&D, Pfizer Worldwide R&D, Pearl River, New York 10965, United States
- Worldwide Medicinal Chemistry, and §Global Biotherapeutics Technologies, Pfizer Worldwide R&D, Cambridge, Massachusetts 02139, United States
| | - Michael Green
- Pharmacokinetics, Dynamics and Metabolism, ∥Worldwide Medicinal Chemistry, and ¶Pharmaceutical Sciences Chemical R&D, Pfizer Worldwide R&D, Groton, Connecticut 06340, United States
- Oncology Research Unit, and ⊥Bioprocess R&D, Pfizer Worldwide R&D, Pearl River, New York 10965, United States
- Worldwide Medicinal Chemistry, and §Global Biotherapeutics Technologies, Pfizer Worldwide R&D, Cambridge, Massachusetts 02139, United States
| | - My-Hanh Lam
- Pharmacokinetics, Dynamics and Metabolism, ∥Worldwide Medicinal Chemistry, and ¶Pharmaceutical Sciences Chemical R&D, Pfizer Worldwide R&D, Groton, Connecticut 06340, United States
- Oncology Research Unit, and ⊥Bioprocess R&D, Pfizer Worldwide R&D, Pearl River, New York 10965, United States
- Worldwide Medicinal Chemistry, and §Global Biotherapeutics Technologies, Pfizer Worldwide R&D, Cambridge, Massachusetts 02139, United States
| | - Frank Loganzo
- Pharmacokinetics, Dynamics and Metabolism, ∥Worldwide Medicinal Chemistry, and ¶Pharmaceutical Sciences Chemical R&D, Pfizer Worldwide R&D, Groton, Connecticut 06340, United States
- Oncology Research Unit, and ⊥Bioprocess R&D, Pfizer Worldwide R&D, Pearl River, New York 10965, United States
- Worldwide Medicinal Chemistry, and §Global Biotherapeutics Technologies, Pfizer Worldwide R&D, Cambridge, Massachusetts 02139, United States
| | - Birte Nolting
- Pharmacokinetics, Dynamics and Metabolism, ∥Worldwide Medicinal Chemistry, and ¶Pharmaceutical Sciences Chemical R&D, Pfizer Worldwide R&D, Groton, Connecticut 06340, United States
- Oncology Research Unit, and ⊥Bioprocess R&D, Pfizer Worldwide R&D, Pearl River, New York 10965, United States
- Worldwide Medicinal Chemistry, and §Global Biotherapeutics Technologies, Pfizer Worldwide R&D, Cambridge, Massachusetts 02139, United States
| | - Betsy Pierce
- Pharmacokinetics, Dynamics and Metabolism, ∥Worldwide Medicinal Chemistry, and ¶Pharmaceutical Sciences Chemical R&D, Pfizer Worldwide R&D, Groton, Connecticut 06340, United States
- Oncology Research Unit, and ⊥Bioprocess R&D, Pfizer Worldwide R&D, Pearl River, New York 10965, United States
- Worldwide Medicinal Chemistry, and §Global Biotherapeutics Technologies, Pfizer Worldwide R&D, Cambridge, Massachusetts 02139, United States
| | - Sujiet Puthenveetil
- Pharmacokinetics, Dynamics and Metabolism, ∥Worldwide Medicinal Chemistry, and ¶Pharmaceutical Sciences Chemical R&D, Pfizer Worldwide R&D, Groton, Connecticut 06340, United States
- Oncology Research Unit, and ⊥Bioprocess R&D, Pfizer Worldwide R&D, Pearl River, New York 10965, United States
- Worldwide Medicinal Chemistry, and §Global Biotherapeutics Technologies, Pfizer Worldwide R&D, Cambridge, Massachusetts 02139, United States
| | - Lee Roberts
- Pharmacokinetics, Dynamics and Metabolism, ∥Worldwide Medicinal Chemistry, and ¶Pharmaceutical Sciences Chemical R&D, Pfizer Worldwide R&D, Groton, Connecticut 06340, United States
- Oncology Research Unit, and ⊥Bioprocess R&D, Pfizer Worldwide R&D, Pearl River, New York 10965, United States
- Worldwide Medicinal Chemistry, and §Global Biotherapeutics Technologies, Pfizer Worldwide R&D, Cambridge, Massachusetts 02139, United States
| | - Klaas Schildknegt
- Pharmacokinetics, Dynamics and Metabolism, ∥Worldwide Medicinal Chemistry, and ¶Pharmaceutical Sciences Chemical R&D, Pfizer Worldwide R&D, Groton, Connecticut 06340, United States
- Oncology Research Unit, and ⊥Bioprocess R&D, Pfizer Worldwide R&D, Pearl River, New York 10965, United States
- Worldwide Medicinal Chemistry, and §Global Biotherapeutics Technologies, Pfizer Worldwide R&D, Cambridge, Massachusetts 02139, United States
| | - Chakrapani Subramanyam
- Pharmacokinetics, Dynamics and Metabolism, ∥Worldwide Medicinal Chemistry, and ¶Pharmaceutical Sciences Chemical R&D, Pfizer Worldwide R&D, Groton, Connecticut 06340, United States
- Oncology Research Unit, and ⊥Bioprocess R&D, Pfizer Worldwide R&D, Pearl River, New York 10965, United States
- Worldwide Medicinal Chemistry, and §Global Biotherapeutics Technologies, Pfizer Worldwide R&D, Cambridge, Massachusetts 02139, United States
| |
Collapse
|
11
|
Puthenveetil S, Musto S, Loganzo F, Tumey LN, O'Donnell CJ, Graziani E. Development of Solid-Phase Site-Specific Conjugation and Its Application toward Generation of Dual Labeled Antibody and Fab Drug Conjugates. Bioconjug Chem 2016; 27:1030-9. [PMID: 26942771 DOI: 10.1021/acs.bioconjchem.6b00054] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
The focus of the antibody-drug conjugate (ADC) field is shifting toward development of site-specific, next-generation ADCs to address the issue of heterogeneity, metabolic instability, conjugatability, and less than ideal therapeutic index associated with the conventional (heterogeneous) ADCs. It is evident from the recent literature that the site of conjugation, the structure of the linker, and the physicochemical properties of the linker-payload all have a significant impact on the safety and efficacy of the resulting ADCs. Screening multiple linker-payloads on multiple sites of an antibody presents a combinatorial problem that necessitates high-throughput conjugation and purification methodology to identify ADCs with the best combination of site and payload. Toward this end, we developed a protein A/L-based solid-phase, site-specific conjugation and purification method that can be used to generate site-specific ADCs in a 96-well plate format. This solid-phase method has been shown to be versatile because of its compatibility with various conjugation functional handles such as maleimides, haloacetamides, copper free click substrates, and transglutaminase substrates. The application of this methodology was further expanded to generate dual labeled, site-specific antibody and Fab conjugates.
Collapse
Affiliation(s)
- Sujiet Puthenveetil
- Worldwide Medicinal Chemistry, Pfizer Global R&D , Groton, Connecticut 06340, United States
| | - Sylvia Musto
- Pfizer Oncology-Rinat R&D , 401 North Middletown Road, Pearl River, New York 10965, United States
| | - Frank Loganzo
- Pfizer Oncology-Rinat R&D , 401 North Middletown Road, Pearl River, New York 10965, United States
| | - L Nathan Tumey
- Worldwide Medicinal Chemistry, Pfizer Global R&D , Groton, Connecticut 06340, United States
| | | | - Edmund Graziani
- Worldwide Medicinal Chemistry, Pfizer Global R&D , Groton, Connecticut 06340, United States
| |
Collapse
|
12
|
Puthenveetil S, Liu DS, White KA, Thompson S, Ting AY. Yeast display evolution of a kinetically efficient 13-amino acid substrate for lipoic acid ligase. J Am Chem Soc 2010; 131:16430-8. [PMID: 19863063 DOI: 10.1021/ja904596f] [Citation(s) in RCA: 81] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Escherichia coli lipoic acid ligase (LplA) catalyzes ATP-dependent covalent ligation of lipoic acid onto specific lysine side chains of three acceptor proteins involved in oxidative metabolism. Our lab has shown that LplA and engineered mutants can ligate useful small-molecule probes such as alkyl azides ( Nat. Biotechnol. 2007 , 25 , 1483 - 1487 ) and photo-cross-linkers ( Angew. Chem., Int. Ed. 2008 , 47 , 7018 - 7021 ) in place of lipoic acid, facilitating imaging and proteomic studies. Both to further our understanding of lipoic acid metabolism, and to improve LplA's utility as a biotechnological platform, we have engineered a novel 13-amino acid peptide substrate for LplA. LplA's natural protein substrates have a conserved beta-hairpin structure, a conformation that is difficult to recapitulate in a peptide, and thus we performed in vitro evolution to engineer the LplA peptide substrate, called "LplA Acceptor Peptide" (LAP). A approximately 10(7) library of LAP variants was displayed on the surface of yeast cells, labeled by LplA with either lipoic acid or bromoalkanoic acid, and the most efficiently labeled LAP clones were isolated by fluorescence activated cell sorting. Four rounds of evolution followed by additional rational mutagenesis produced a "LAP2" sequence with a k(cat)/K(m) of 0.99 muM(-1) min(-1), >70-fold better than our previous rationally designed 22-amino acid LAP1 sequence (Nat. Biotechnol. 2007, 25, 1483-1487), and only 8-fold worse than the k(cat)/K(m) values of natural lipoate and biotin acceptor proteins. The kinetic improvement over LAP1 allowed us to rapidly label cell surface peptide-fused receptors with quantum dots.
Collapse
Affiliation(s)
- Sujiet Puthenveetil
- Department of Chemistry, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, Massachusetts 02139, USA
| | | | | | | | | |
Collapse
|
13
|
Baruah H, Puthenveetil S, Choi YA, Shah S, Ting AY. An engineered aryl azide ligase for site-specific mapping of protein-protein interactions through photo-cross-linking. Angew Chem Int Ed Engl 2008; 47:7018-21. [PMID: 18677791 DOI: 10.1002/anie.200802088] [Citation(s) in RCA: 75] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Affiliation(s)
- Hemanta Baruah
- Department of Chemistry, Room 18-496, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | | | | | | | | |
Collapse
|
14
|
Baruah H, Puthenveetil S, Choi YA, Shah S, Ting A. An Engineered Aryl Azide Ligase for Site-Specific Mapping of Protein-Protein Interactions through Photo-Cross-Linking. Angew Chem Int Ed Engl 2008. [DOI: 10.1002/ange.200802088] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
15
|
Howarth M, Liu W, Puthenveetil S, Zheng Y, Marshall LF, Schmidt MM, Wittrup KD, Bawendi MG, Ting AY. Monovalent, reduced-size quantum dots for imaging receptors on living cells. Nat Methods 2008; 5:397-9. [PMID: 18425138 DOI: 10.1038/nmeth.1206] [Citation(s) in RCA: 356] [Impact Index Per Article: 22.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2007] [Accepted: 03/24/2008] [Indexed: 11/09/2022]
Abstract
We describe a method to generate monovalent quantum dots (QDs) using agarose gel electrophoresis. We passivated QDs with a carboxy-terminated polyethylene-glycol ligand, yielding particles with half the diameter of commercial QDs, which we conjugated to a single copy of a high-affinity targeting moiety (monovalent streptavidin or antibody to carcinoembryonic antigen) to label cell-surface proteins. The small size improved access of QD-labeled glutamate receptors to neuronal synapses, and monovalency prevented EphA3 tyrosine kinase activation.
Collapse
Affiliation(s)
- Mark Howarth
- Department of Chemistry, 77 Massachusetts Avenue, Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Puthenveetil S, Whitby L, Ren J, Kelnar K, Krebs JF, Beal PA. Controlling activation of the RNA-dependent protein kinase by siRNAs using site-specific chemical modification. Nucleic Acids Res 2006; 34:4900-11. [PMID: 16982647 PMCID: PMC1635244 DOI: 10.1093/nar/gkl464] [Citation(s) in RCA: 65] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
The RNA-dependent protein kinase (PKR) is activated by binding to double-stranded RNA (dsRNA). Activation of PKR by short-interfering RNAs (siRNAs) and stimulation of the innate immune response has been suggested to explain certain off-target effects in some RNA interference experiments. Here we show that PKR's kinase activity is stimulated in vitro 3- to 5-fold by siRNA duplexes with 19 bp and 2 nt 3′-overhangs, whereas the maximum activation observed for poly(I)•poly(C) was 17-fold over background under the same conditions. Directed hydroxyl radical cleavage experiments indicated that siRNA duplexes have at least four different binding sites for PKR's dsRNA binding motifs (dsRBMs). The location of these binding sites suggested specific nucleotide positions in the siRNA sense strand that could be modified with a corresponding loss of PKR binding. Modification at these sites with N2-benzyl-2′-deoxyguanosine (BndG) blocked interaction with PKR's dsRBMs and inhibited activation of PKR by the siRNA. Importantly, modification of an siRNA duplex that greatly reduced PKR activation did not prevent the duplex from lowering mRNA levels of a targeted message by RNA interference in HeLa cells. Thus, these studies demonstrate that specific positions in an siRNA can be rationally modified to prevent interaction with components of cellular dsRNA-regulated pathways.
Collapse
Affiliation(s)
| | | | | | - Kevin Kelnar
- Ambion, Inc.2130 Woodward, Austin, TX 78744, USA
| | | | - Peter A. Beal
- To whom correspondence should be addressed. Fax: +1 801 581 8433;
| |
Collapse
|
17
|
Puthenveetil S, Véliz EA, Beal PA. Site-specific modification of Epstein-Barr virus-encoded RNA 1 with N2-benzylguanosine limits the binding sites occupied by PKR. Chembiochem 2004; 5:383-6. [PMID: 14997533 DOI: 10.1002/cbic.200300816] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- Sujiet Puthenveetil
- University of Utah, Department of Chemistry, Salt Lake City, Utah 84112, USA
| | | | | |
Collapse
|
18
|
Puthenveetil S, Véliz EA, Beal PA. Cover Picture: Site-Specific Modification of Epstein-Barr Virus-Encoded RNA 1 with N2-Benzylguanosine Limits the Binding Sites Occupied by PKR (ChemBioChem 3/2004). Chembiochem 2004. [DOI: 10.1002/cbic.200490003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|